ECSP056006A - Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas - Google Patents
Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadasInfo
- Publication number
- ECSP056006A ECSP056006A EC2005006006A ECSP056006A ECSP056006A EC SP056006 A ECSP056006 A EC SP056006A EC 2005006006 A EC2005006006 A EC 2005006006A EC SP056006 A ECSP056006 A EC SP056006A EC SP056006 A ECSP056006 A EC SP056006A
- Authority
- EC
- Ecuador
- Prior art keywords
- rapamycin
- inflammatory
- derivative
- treatment
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente invención se refiere a composiciones farmacéuticas que comprenden en combinación rapamicina o un derivado de rapamicina y un compuesto de la fórmula I, por ejemplo, útiles para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas, incluyendo enfermedades autoinmunes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0306070A GB0306070D0 (en) | 2003-03-17 | 2003-03-17 | Organic compounds |
GB0306868A GB0306868D0 (en) | 2003-03-25 | 2003-03-25 | Organic compounds |
GB0319226A GB0319226D0 (en) | 2003-08-15 | 2003-08-15 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP056006A true ECSP056006A (es) | 2006-01-27 |
Family
ID=33032928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005006006A ECSP056006A (es) | 2003-03-17 | 2005-09-08 | Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas |
Country Status (26)
Country | Link |
---|---|
US (1) | US20060154952A1 (es) |
EP (1) | EP1608368B8 (es) |
JP (1) | JP2006515017A (es) |
KR (1) | KR100855140B1 (es) |
AR (1) | AR043504A1 (es) |
AT (1) | ATE409479T1 (es) |
AU (1) | AU2004222563B2 (es) |
BR (1) | BRPI0408423A (es) |
CA (2) | CA2633287A1 (es) |
CL (1) | CL2004000535A1 (es) |
DE (1) | DE602004016830D1 (es) |
EC (1) | ECSP056006A (es) |
ES (1) | ES2315648T3 (es) |
HK (1) | HK1086743A1 (es) |
HR (1) | HRP20050800A2 (es) |
IS (1) | IS8028A (es) |
MA (1) | MA27671A1 (es) |
MX (1) | MXPA05009934A (es) |
MY (1) | MY137868A (es) |
NO (1) | NO20054778L (es) |
PE (1) | PE20050313A1 (es) |
PL (1) | PL1608368T3 (es) |
PT (1) | PT1608368E (es) |
TN (1) | TNSN05197A1 (es) |
TW (2) | TW200503703A (es) |
WO (1) | WO2004082681A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1804779A1 (en) * | 2004-10-28 | 2007-07-11 | Wyeth | Use of an mtor inhibitor in treatment of uterine leiomyoma |
CA2719134C (en) * | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
AU2013205002B2 (en) * | 2008-03-21 | 2016-09-15 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
JP5766124B2 (ja) | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
RU2449806C1 (ru) * | 2010-11-30 | 2012-05-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ лечения красного плоского лишая слизистой оболочки полости рта |
US10172789B2 (en) | 2013-01-24 | 2019-01-08 | Palvella Therapeutics Llc | Compositions for transdermal delivery of mTOR inhibitors |
AU2014332080B2 (en) | 2013-10-08 | 2020-02-27 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
JP6525285B2 (ja) * | 2014-04-04 | 2019-06-05 | エイアイ・セラピューティクス・インコーポレーテッド | 加齢関連状態を処置するための吸入可能なラパマイシン配合物 |
KR20170095807A (ko) | 2014-10-07 | 2017-08-23 | 램 테라퓨틱스, 인코포레이티드 | 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제 |
MX2017012966A (es) | 2015-04-10 | 2018-06-06 | Amgen Inc | Muteinas de interleuquina 2 para la expansion de celulas t regulatorias. |
EP3565520A4 (en) | 2017-01-06 | 2020-08-19 | Palvella Therapeutics, Inc. | Anhydrous compositions of MTOR inhibitors and method of use |
US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0427680B1 (en) * | 1989-11-09 | 1995-08-23 | Sandoz Ltd. | Heteroatoms-containing tricyclic compounds |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
ATE340586T1 (de) * | 1996-07-30 | 2006-10-15 | Novartis Pharma Gmbh | Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände |
GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
WO2002089796A2 (en) * | 2001-05-09 | 2002-11-14 | Novartis Ag | Methods for selective immunomodulation using pimecrolimus |
CN1615137A (zh) * | 2002-01-10 | 2005-05-11 | 诺瓦提斯公司 | 用于预防和治疗血管疾病、包含雷帕霉素及其衍生物的药物递送系统 |
WO2003094991A1 (de) * | 2002-05-09 | 2003-11-20 | Hemoteq Gmbh | Hemokompatibel beschichtete medizinprodukte, deren herstellung und verwendung |
-
2004
- 2004-03-08 AR ARP040100730A patent/AR043504A1/es not_active Application Discontinuation
- 2004-03-15 PE PE2004000273A patent/PE20050313A1/es not_active Application Discontinuation
- 2004-03-15 TW TW093106848A patent/TW200503703A/zh unknown
- 2004-03-15 TW TW097116133A patent/TW200835484A/zh unknown
- 2004-03-16 AU AU2004222563A patent/AU2004222563B2/en not_active Ceased
- 2004-03-16 PT PT04720871T patent/PT1608368E/pt unknown
- 2004-03-16 BR BRPI0408423-3A patent/BRPI0408423A/pt not_active IP Right Cessation
- 2004-03-16 AT AT04720871T patent/ATE409479T1/de not_active IP Right Cessation
- 2004-03-16 US US10/547,185 patent/US20060154952A1/en not_active Abandoned
- 2004-03-16 KR KR1020057017469A patent/KR100855140B1/ko not_active IP Right Cessation
- 2004-03-16 JP JP2005518678A patent/JP2006515017A/ja active Pending
- 2004-03-16 EP EP04720871A patent/EP1608368B8/en not_active Expired - Lifetime
- 2004-03-16 ES ES04720871T patent/ES2315648T3/es not_active Expired - Lifetime
- 2004-03-16 MY MYPI20040914A patent/MY137868A/en unknown
- 2004-03-16 WO PCT/EP2004/002714 patent/WO2004082681A1/en active IP Right Grant
- 2004-03-16 PL PL04720871T patent/PL1608368T3/pl unknown
- 2004-03-16 MX MXPA05009934A patent/MXPA05009934A/es not_active Application Discontinuation
- 2004-03-16 CL CL200400535A patent/CL2004000535A1/es unknown
- 2004-03-16 CA CA002633287A patent/CA2633287A1/en not_active Abandoned
- 2004-03-16 DE DE602004016830T patent/DE602004016830D1/de not_active Expired - Fee Related
- 2004-03-16 CA CA002517671A patent/CA2517671A1/en not_active Abandoned
-
2005
- 2005-08-17 TN TNP2005000197A patent/TNSN05197A1/en unknown
- 2005-09-08 EC EC2005006006A patent/ECSP056006A/es unknown
- 2005-09-12 HR HR20050800A patent/HRP20050800A2/xx not_active Application Discontinuation
- 2005-09-15 IS IS8028A patent/IS8028A/is unknown
- 2005-09-30 MA MA28526A patent/MA27671A1/fr unknown
- 2005-10-17 NO NO20054778A patent/NO20054778L/no not_active Application Discontinuation
-
2006
- 2006-06-13 HK HK06106761.8A patent/HK1086743A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR100855140B1 (ko) | 2008-08-28 |
TNSN05197A1 (en) | 2007-06-11 |
HK1086743A1 (en) | 2006-09-29 |
CA2517671A1 (en) | 2004-09-30 |
WO2004082681B1 (en) | 2004-11-25 |
JP2006515017A (ja) | 2006-05-18 |
US20060154952A1 (en) | 2006-07-13 |
EP1608368A1 (en) | 2005-12-28 |
DE602004016830D1 (de) | 2008-11-13 |
WO2004082681A1 (en) | 2004-09-30 |
MY137868A (en) | 2009-03-31 |
PE20050313A1 (es) | 2005-06-14 |
TW200835484A (en) | 2008-09-01 |
CL2004000535A1 (es) | 2005-01-14 |
NO20054778D0 (no) | 2005-10-17 |
MXPA05009934A (es) | 2006-03-21 |
PL1608368T3 (pl) | 2009-03-31 |
MA27671A1 (fr) | 2005-12-01 |
NO20054778L (no) | 2005-12-19 |
TW200503703A (en) | 2005-02-01 |
EP1608368B1 (en) | 2008-10-01 |
BRPI0408423A (pt) | 2006-03-21 |
ATE409479T1 (de) | 2008-10-15 |
AU2004222563A1 (en) | 2004-09-30 |
PT1608368E (pt) | 2009-01-27 |
AR043504A1 (es) | 2005-08-03 |
KR20050110023A (ko) | 2005-11-22 |
ES2315648T3 (es) | 2009-04-01 |
IS8028A (is) | 2005-09-15 |
EP1608368B8 (en) | 2009-06-10 |
AU2004222563B2 (en) | 2006-11-02 |
CA2633287A1 (en) | 2004-09-30 |
HRP20050800A2 (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP056006A (es) | Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas | |
HN2012001162A (es) | Triazolopiridinas | |
ECSP066717A (es) | Compuestos de quinolina sustituidos | |
CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
SV2005001973A (es) | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500) | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
ATE495743T1 (de) | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten | |
TW200718422A (en) | 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | |
ECSP078060A (es) | 2,4-diamino-pirimidinas como inhibidores de aurora | |
EA200802390A1 (ru) | Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их | |
NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
ECSP099371A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
AR050717A1 (es) | Composiciones farmaceuticas | |
CR9347A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
ATE538124T1 (de) | Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit | |
UY31457A1 (es) | Derivados acidos de cicloalquilamino | |
CY1109992T1 (el) | Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα | |
GT200500310A (es) | Compuestos organicos | |
NO20063293L (no) | Farmasoytiske forbindelser | |
NI200300045A (es) | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. | |
CL2009000599A1 (es) | Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras. | |
ATE474574T1 (de) | Imidazoazephinonverbindungen | |
AR111697A2 (es) | Composición oftálmica para el tratamiento de las alergias oculares | |
UY29308A1 (es) | Derivado de quinolina, su uso, preparación y medicamento que lo contiene |